Persistent, Recurrent, or Metastatic Cervical Cancer Clinical Trials in Rio de Janeiro, Rio de Janeiro

Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer.